Incidence d’atteinte hépatique avancée dans une cohorte de patients co-infectés VIH et hépatite B
Carmelo Lafuente‐Lafuente(Assistance Publique – Hôpitaux de Paris), Jean‐François Bergmann(Northern General Hospital), Inmaculada Jarrín(Instituto de Salud Carlos III), Pierre‐Olivier Sellier(Hôpital Lariboisière), Guy G. Simoneau(Hôpital Fernand-Widal), Myriam Diemer(Hôpital Lariboisière), Nathalie Schnepf(Assistance Publique – Hôpitaux de Paris), V. Delcey(Hôpital Fernand-Widal), M.C. Mazeron(Hôpital Lariboisière), S. Mouly(Hôpital Lariboisière)
Cited by 0
Related Papers
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
|The Lancet Infectious Diseases|2017|587
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342
Validation of a specific quality of life questionnaire for functional digestive disorders
|Gut|1999|181
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
|Clinical Microbiology and Infection|2020|128